Methyl 3-cyclopropyl-3-(3-hydroxyphenyl)-2-methylpropanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Methyl 3-cyclopropyl-3-(3-hydroxyphenyl)-2-methylpropanoate
• 英文别名: methyl 3-cyclopropyl-3-(3-hydroxyphenyl)-2-methylpropanoate
• 化学式: C₁₄H₁₈O₃
• 分子量: 234.29
• InChiKey: XTKAMBAWNHTBEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES<br/>[FR] AGONISTES CYCLOHEXYLE DE GPR40 POUR LE TRAITEMENT DU DIABÈTE DE TYPE 2
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018081047A1

  公开（公告）日：2018-05-03

  Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: (Formula (I)) wherein R1, R2, R3, A, W, L, Ra, and G are defined herein: and by Formula (II) as follows: (Formula (II)) wherein R1B, WB, LB, and GB are defined herein.

  披露了用于治疗受GPR40受体调节影响的疾病的化合物、组合物和方法。这类化合物由公式(I)表示，如下所示：(公式(I))，其中R1、R2、R3、A、W、L、Ra和G在本文中定义；以及由公式(II)表示，如下所示：(公式(II))，其中R1B、WB、LB和GB在本文中定义。
• [EN] GPR40 AGONISTS<br/>[FR] AGONISTES DE GPR40
  申请人：KALLYOPE INC

  公开号：WO2020242943A1

  公开（公告）日：2020-12-03

  This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

  这份公开信息至少部分涉及用于治疗涉及肠-脑轴的条件或疾病的GPR40激动剂。在某些实施例中，GPR40激动剂是肠道限制性化合物。在某些实施例中，GPR40激动剂是全激动剂或部分激动剂。在某些实施例中，所述条件或疾病是一种代谢紊乱，如糖尿病、肥胖、非酒精性脂肪肝炎（NASH）或一种营养紊乱，如短肠综合征。
• [EN] ANTIDIABETIC BICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS BICYCLIQUES ANTIDIABÉTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016022742A1

  公开（公告）日：2016-02-11

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  结构式（I）的新化合物及其药用盐是G蛋白偶联受体40（GPR40）的激动剂，可能对通过G蛋白偶联受体40介导的疾病的治疗、预防和抑制具有用处。本发明的化合物可能对2型糖尿病的治疗有用，以及对常与该疾病相关的疾病，包括肥胖和脂质紊乱，如混合型或糖尿病性脂质代谢异常、高脂血症、高胆固醇血症和高甘油三酯血症的治疗有用。
• [EN] [5,6]-FUSED BICYCLIC ANTIDIABETIC COMPOUNDS<br/>[FR] COMPOSÉS ANTIDIABÉTIQUES BICYCLIQUES À FUSION [5,6]
  申请人：MERCK SHARP & DOHME

  公开号：WO2016022446A1

  公开（公告）日：2016-02-11

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  结构式（I）的新化合物及其药用盐是G蛋白偶联受体40（GPR40）的激动剂，可能在治疗、预防和抑制由G蛋白偶联受体40介导的疾病方面具有用处。本发明的化合物可能在治疗2型糖尿病以及与该疾病经常相关的疾病，包括肥胖和脂质紊乱等条件中具有用处，如混合型或糖尿病性脂质代谢异常、高脂血症、高胆固醇血症和高甘油三酯血症。
• ANTIDIABETIC BICYCLIC COMPOUNDS
  申请人：BROCKUNIER Linda L.

  公开号：US20160002255A1

  公开（公告）日：2016-01-07

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  结构式（I）的新化合物及其药学上可接受的盐是G蛋白偶联受体40 (GPR40) 的激动剂，可用于治疗、预防和抑制由G蛋白偶联受体40介导的疾病。本发明的化合物可用于治疗2型糖尿病，以及与该疾病常见相关的疾病，包括肥胖和脂质紊乱，如混合型或糖尿病性脂质代谢异常、高脂血症、高胆固醇血症和高三酰甘油血症。